A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE)

Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 48

Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 24, Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 12, Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48, Achievement of LLDAS in ≥50% of post Baseline visits through Week 48, Change from Baseline in SLEDAI-2K at Week 48, Achievement of BILAG 2004 improvement without worsening at Week 48, Change from Baseline in PGA at Week 48, Achievement of SRI 4 response at Week 48, Achievement of prevention of moderate/severe BILAG flares (moderate/severe BILAG flarefree) through Week 48, Time to severe BILAG flare through Week 48, Time to moderate/severe BILAG flare through Week 48, Percentage of participants with treatment-emergent adverse events (TEAEs) during the study, Percentage of participants with serious treatment-emergent adverse events during the study, Percentage of participants with treatment-emergent adverse events of special interest during the study, Percentage of participants with treatment-emergent adverse events of special monitoring during the study

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Belgium, Denmark, France, Germany, Greece, Italy, Netherlands, Poland, Spain